Compare Eli Lilly And Co (LLY) vs Simon Property Group Inc (SPG) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

SPG trades at $228.53, down 0.07% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.48 versus $1.46, maintaining a three-quarter beat streak. Revenue growth continues from $6.0B in 2024 to $6.4B in 2025, supported by strong leasing activity and portfolio redevelopment. The stock offers a 4% dividend yield with recent H1-26 payment of $2.25 declared.

SPG presents a compelling investment case with strong operational performance and upward earnings revisions, though elevated valuation metrics and significant long-term debt of $24.21B warrant caution. Analyst consensus leans positive with 40.5% buy ratings but mixed sentiment reflects concerns about e-commerce competition and interest rate sensitivity. The current price sits above the $214.40 consensus target, suggesting limited near-term upside potential despite solid fundamentals.